Mirum Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 89 to 93.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they launch their biggest climbs.
How To Use Stock Charts To Stay Profitable And Protected
Mirum Pharmaceuticals broke out earlier, but has fallen back below the prior 45.23 entry from a consolidation. If a stock you're tracking clears a buy point then retreats 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new chart pattern and buy point. Also understand that the most recent consolidation is a later-stage base, and those involve more risk.
The company reported 0% EPS growth last quarter, while sales growth came in at 89%.
The company earns the No. 14 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
